Skip to main content

Table 6 Bioclinical features of the tumours of the validation set forming the molecular subgroups as defined by the Chi2 analysis

From: A new molecular breast cancer subclass defined from a large scale real-time quantitative RT-PCR study

Subgroup Number of tumours Hormonal status Age Tumour size Histological grade (SBR) Clinical outcome
  n % ER+ % ER- % <50 years % <20 mm % SBRI % SBRII % SBRIII % recurrence
SG1 7 100 0 71 43 0 71 29 43
SG2 1 100 0 100 100 0 0 100 0
SG3/4 28 93 7 39 46 18 39 43 46
SG6 18 89 11 67 78 22 39 39 28
SG7 11 82 18 73 82 27 9 64 27
SG9 14 57 43 64 36 0 0 100 57
SG10 30 30 70 70 40 3 17 80 53
Overall cohort 109 70 30 61 52 12 27 61 44